Pfizer TUKYSA gains FDA approval for first-line HER2-positive metastatic breast cancer maintenance
Pfizer’s TUKYSA gained first-line HER2-positive breast cancer maintenance approval after extending median PFS by 8.6 months.
Features & Analysis
Pharma & Biotech
Pfizer’s Ibrance wins broader FDA role as metastatic breast cancer treatment becomes more complex
The FDA approval brings CDK4/6 inhibition into HR-positive, HER2-positive metastatic breast cancer maintenance, although toxicity, immature survival data and a rapidly changing first-line market could shape adoption.
Pharma & Biotech
Genentech’s ASCO 2026 data puts giredestrant at the centre of Roche’s breast cancer strategy
Endocrine therapy is crowded. Genentech needs giredestrant to prove it can shift breast cancer care, not just add another option.